Eli Lilly and Company

Lmmunometabolism Development Company, LLC

Oliver Schroeder

Jonathan Wesley Day

Robert William Siegel

Qing Chai

Robert John Konrad

Yuewei Qian

Julian Davies

Andrea Paula Martin

Stuart W Bright

Karen L Cox

Chetankumar Natvarlal Patel

Wei Wang

Kira Vladimirovna Rubtsova

Sean Edward Sissons

Xiao-Fen Wang

Angus John MacDonald

Fabio Magrini

Neelufar Mozaffarian

Joshua Dade Poorbaugh

Frank Charles Dorsey

Joseph Benjamin Granger

Stuart Willis Bright

Karen Leigh Cox

Angus John Macdonald

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodies bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

Anti-ANGPTL 3/8 complex antibodies and methods of using the same

The present invention relates to antibodies that specifically bind human monocarboxylate transporter 1 (MCT1) ('anti-human MCT1 antibodies'), compositions comprising such anti-human MCT1 antibodies, and methods of using such anti-human MCT1 antibodies.

Human monocarboxylate transporter 1 antibodies and uses thereof

Angiopoietin-like protein (ANGPTL)3/8 fusion proteins are disclosed. Nucleic acid constructs encoding ANGPTL3/8 fusion proteins also are disclosed. Methods of making and using the same also are disclosed, especially for generating antibodies against ANGPTL3 and/or ANGPTL8.

Polynucleotides for preparing ANGPTL 3/8 complexes

Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.

Methods of detecting human IL-21

Anti-ANGPTL &#x215c; complex antibodies and methods of using the same

Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.

ANGPTL3/8 complexes and methods of using the same

The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.

IL-21 antibodies and methods of making or using the antibodies

Growing community of inventors

Encinitas, CA, United States of America

Oliver Schroeder